Allovectin-7 (velimogene aliplasmid) - AnGes MG, Brickell
Citi Global Healthcare Conference (Vical) - Mar 3, 2011 - Allovectin-7 / Vical;   P3 ongoing with commercial opportunity >$500 million & database lock expected in H2 ‘11 for MM 
Melanoma
http://www.larvolonline.com/tlg/ccdb/VicalCitiGlobalHealthcareConfMar3.pdf
 
Mar 3, 2011
 
 
27f04e5e-6e64-495c-99c8-9f3fb0906325.png